A research programme by the Access to Medicine Foundation
  • Events
  • Webinar: Access to Vaccines Index webinar for investor...
Webinar - Event date: 31 May 2017

Access to Vaccines Index webinar for investors – co hosted by PRI and ICCR

On Wednesday 31 May, the Interfaith Center on Corporate Responsibility (ICCR), the Principles for Responsible Investment (PRI) and the Access to Medicine Foundation, will co-host an investor webinar about the recently published Access to Vaccines Index. The focus will be on access to vaccines as a material issue for investors in pharmaceutical companies and how the Access to Vaccines Index can be used as a tool for change.

Participants will discuss why access to vaccines is a material issue for investors in pharmaceutical companies and how the Access to Vaccines Index can be used as a tool to improve the availability and affordability of vaccines in low- and middle-income countries.

Speakers include:

  • Jayasree K. Iyer – Executive Director, Access to Medicine Foundation
  • Lauren Compere – Managing Director and Director of Shareholder Engagement at Boston Common Asset Management; Board Member, ICCR
  • Jon Pender – Vice President, Government Affairs, GSK; and Guy Pickles –Senior Manager, Global Health, GSK Vaccines.
  • Hanneke Schuitemaker – Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention (Johnson & Johnson)

The webinar will take place on Wednesday, 31 May at 10:00 EDT/16:00 CEST and will be moderated by Alison Biscoe from PRI. If you have questions for the speakers, you can send them in advance to Alison.Biscoe@unpri.org

You can register for the webinar here.

The Access to Vaccines Index covers:

  • 8 companies (Daiichi Sankyo, GSK, Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India and Takeda);
  • 3 areas of corporate behaviour (research & development; pricing & registration; and manufacturing & supply);
  • 69 diseases with the highest priority for improving access to immunisation (including pneumococcal disease, meningococcal disease, seasonal influenza, polio and Ebola).

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.